Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Post and Core

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43895   clinical trials with a EudraCT protocol, of which   7301   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    500 result(s) found for: Post and Core. Displaying page 1 of 25.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2013-002539-13 Sponsor Protocol Number: CARE-ROP Start Date*: 2014-04-01
    Sponsor Name:University Medical Center Freiburg
    Full Title: Multicenter randomized double masked parallel design exploratory study to assess safety and efficacy of two different doses of intravitreal anti-VEGF treatment with ranibizumab (0.12 mg vs. 0.20 mg...
    Medical condition: retinopathy of prematurity
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10038974 Retrolental fibroplasia LLT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: DE (Restarted)
    Trial results: (No results available)
    EudraCT Number: 2019-003230-17 Sponsor Protocol Number: CAIN457M2301E1 Start Date*: 2020-01-22
    Sponsor Name:Novartis Pharma AG
    Full Title: A Multicenter, Double-blind, Randomized Withdrawal extension study of subcutaneous secukinumab to demonstrate long-term efficacy, safety and tolerability in subjects with moderate to severe hidrade...
    Medical condition: hidradenitis suppurativa
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Ongoing) GR (Ongoing) ES (Ongoing) FR (Ongoing) PT (Ongoing) CZ (Ongoing) SK (Ongoing) LT (Ongoing) AT (Ongoing) NL (Ongoing) DK (Prematurely Ended) IT (Ongoing) HR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-000668-17 Sponsor Protocol Number: CZOL446H2301 E1 Start Date*: 2005-07-12
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 3 year, double-blind extension to CZOL446H2301 to evaluate the long term safety and efficacy of zoledronic acid in the treatment of osteoporosis in postmenopausal women taking calcium and vitamin D.
    Medical condition: Osteoporosis in postmenopausal women
    Disease: Version SOC Term Classification Code Term Level
    9.1 10031282 Osteoporosis LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) GB (Completed) BE (Completed) SE (Completed) FI (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-011622-34 Sponsor Protocol Number: CAIN457A2206E1 Start Date*: 2010-04-26
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open label non-randomized extension study to evaluate the safety and tolerability of AIN457 (anti interleukin-17 monoclonal antibody) in patients with psoriatic arthritis
    Medical condition: Psoriatic arthritis (PsA), which belongs to seronegative spondyloarthropathies (SpA).
    Disease: Version SOC Term Classification Code Term Level
    12.1 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-005777-27 Sponsor Protocol Number: M20-350 Start Date*: 2021-10-08
    Sponsor Name:AbbVie
    Full Title: A Multicenter, Single-Arm Prospective Study to Evaluate Safety and Efficacy of GLE/PIB 8-Week Treatment in Adults and Adolescents with Acute Hepatitis C Virus (HCV) Infection
    Medical condition: Hepatitis C Virus
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) AT (Ongoing) FR (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-002657-36 Sponsor Protocol Number: HMRI2012101/1 Start Date*: 2015-11-13
    Sponsor Name:University of Newcastle
    Full Title: Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation (TASTE) Trial
    Medical condition: Acute Ischaemic Stroke
    Disease: Version SOC Term Classification Code Term Level
    22.1 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) SE (Ongoing) FI (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001615-36 Sponsor Protocol Number: ABY-035-002 Start Date*: 2017-11-14
    Sponsor Name:Affibody AB
    Full Title: A phase II, randomized, parallel group, placebo-controlled, double-blinded, dose-finding study to evaluate efficacy, safety, tolerability, and pharmacokinetics of ABY-035 in subjects with moderate-...
    Medical condition: moderate-to-severe plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-002363-22 Sponsor Protocol Number: IIV-482 Start Date*: 2021-05-27
    Sponsor Name:National Institute for Public Health and the Environment
    Full Title: Vaccination of older persons against Sars-Cov-2 and cellular immunogenicity for long term protection (participating in the Doetinchem Cohort Study)
    Medical condition: SARS-CoV-19, frailty
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-003499-37 Sponsor Protocol Number: DSC/11/2357/44 Start Date*: 2013-01-20
    Sponsor Name:ITALFARMACO
    Full Title: Long-term study evaluating the effect of Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms.
    Medical condition: Chronic myeloproliferative neoplasms (cMPN).
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004851 10028578 Myeloproliferative disorders (excl leukaemias) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing) DE (Completed) PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-004182-26 Sponsor Protocol Number: ELIA Start Date*: 2009-02-02
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Antidepressive efficacy, safety, tolerability and genetic response predictors of lithium augmentation in Escitalopram-treated patients with major depression
    Medical condition: 30-40% of depressed patients do not respond to the first course of drug treatment chosen. Over 50% of nonresponders to the first treatment also do not respond to a second, different treatment . Of ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005899-36 Sponsor Protocol Number: CLOU064C12301 Start Date*: 2022-02-21
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by...
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029205 - Nervous system disorders 10080700 Relapsing multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Ongoing) IT (Ongoing) ES (Ongoing) NL (Ongoing) BE (Ongoing) BG (Ongoing) LV (Ongoing) HR (Ongoing) LT (Ongoing) AT (Ongoing) DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-000661-19 Sponsor Protocol Number: CFEM345EGB07 Start Date*: 2005-11-04
    Sponsor Name:Novartis Pharmaceuticals UK Ltd
    Full Title: Neoadjuvant hormone therapy for postmenopausal women with ER and/or PgR positive primary breast cancer: A multi-center study to determine the optimum length of treatment with Femara (letrozole 2.5m...
    Medical condition: Postmenopausal women with ER and/or PgR positive primary breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005929-89 Sponsor Protocol Number: CLOU064C12302 Start Date*: 2022-02-01
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by...
    Medical condition: Multiple Sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing) IT (Ongoing) GR (Ongoing) ES (Ongoing) PT (Ongoing) SI (Ongoing) SK (Ongoing) BG (Ongoing) PL (Ongoing) HR (Ongoing) EE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-015508-24 Sponsor Protocol Number: CAIN457C2301E1 Start Date*: 2010-02-15
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: Extensión de 38 semanas del Estudio Fase III, multicéntrico, aleatorizado con doble enmascaramiento, controlado con placebo, de determinación de dosis y 24 semanas de duración, con el objetivo de e...
    Medical condition: Terapia adyuvante para el tratamiento de uveitis intermedia, uveitis posterior o panuveitis que precisen inmunosupresión sistémica
    Disease: Version SOC Term Classification Code Term Level
    12.0 10022941 Iridocyclitis LLT
    9 10022557 Intermediate uveitis LLT
    9 10033687 Panuveitis LLT
    9 10036370 Posterior uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002467-26 Sponsor Protocol Number: 480-SFA2013-001 Start Date*: 2013-08-30
    Sponsor Name:480 Biomedical, Inc.
    Full Title: The SPRINT trial: An Evaluation of the 480 Biomedical STANZA™ Drug-Eluting Resorbable Scaffold (DRS) System v1.2 in the Treatment of de novo SFA Lesions
    Medical condition: An evaluation of the safety and performance of the STANZA DRS v1.2 system for the treatment of patients with obstructive superficial femoral artery disease.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-011591-30 Sponsor Protocol Number: CAIN457A2209E1 Start Date*: 2010-09-21
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label non-randomized extension study to evaluate the safety and tolerability of AIN457 (anti interleukin-17 monoclonal antibody) in patients with moderate to severe ankylosing spondylitis
    Medical condition: Ankylosing spondylitis (AS), which belongs to seronegative spondyloarthropathies (SpA).
    Disease: Version SOC Term Classification Code Term Level
    12.0 10002556 Ankylosing spondylitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-004727-18 Sponsor Protocol Number: CORUNO/II/05.1 Start Date*: 2008-06-20
    Sponsor Name:THERABEL PHARMACEUTICAL Ltd
    Full Title: EFFECT OF MOLSIDOMINE 16 MG ADMINISTERED ONCE-DAILY AS A LONG-TERM ADD-ON TREATMENT, ON ATHEROSCLEROSIS PROGRESSION AND INFLAMMATORY BIOMARKERS IN PATIENTS HOSPITALIZED FOR ACUTE CORONARY SYNDROME.
    Medical condition: Randomized, double-blind, placebo-controlled, add-on study in two parallel groups. Patients admitted for Non ST Segment Elevation Acute Coronary Syndromes will undergo a coronary angiography accord...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10011085 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-021900-93 Sponsor Protocol Number: CLIN1001 PCM301 Start Date*: 2010-12-14
    Sponsor Name:STEBA BIOTECH SA
    Full Title: A European randomised Phase 3 study to assess the efficacy and safety of TOOKAD® Soluble for low risk localised prostate cancer compared to Active Surveillance
    Medical condition: Low-risk prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10060862 Prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed) GB (Completed) DE (Completed) NL (Completed) BE (Completed) SE (Completed) FI (Completed) DK (Completed) ES (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003620-16 Sponsor Protocol Number: IIV-465 Start Date*: 2021-05-27
    Sponsor Name:National Institute of Health and the Environment
    Full Title: Vaccine immunogenicity in Dutch frail versus non-frail older individuals (participating in the Doetinchem Cohort study)
    Medical condition: Older adults 73-79 years of age, birth cohorts year 1941-1947, still participating in round 6 of the Doetinchem Cohort Study.
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-013901-33 Sponsor Protocol Number: CAIN457C2303E1 Start Date*: 2009-11-12
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior...
    Medical condition: Adjunctive therapy to standard-of-care for the treatment of posterior uveitis or panuveitis secondary to Behçet's disease
    Disease: Version SOC Term Classification Code Term Level
    12.0 10036370 Posterior uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) ES (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 30 17:50:53 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA